openPR Logo
Press release

Vitiligo Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments | Dermavant Sciences, 2A Pharma, Incyte, Bioscience, Inc., Aclaris Therapeutics, Inc.

04-10-2019 12:01 PM CET | Health & Medicine

Press release from: Vitiligo Therapeutics- Pharma Proff

Vitiligo Therapeutics - Pipeline Analysis 2018, Clinical

Vitiligo is a type of autoimmune disorder which is characterized by white patches on skin. This is mainly due to destruction of melanocytes (cells responsible for pigmentation in the skin). People with certain autoimmune diseases are more prone to developing vitiligo.

Download the sample report at: https://www.pharmaproff.com/request-sample/1019

Some of the most common symptoms of the disease are occurrence of white patches on the hands, feet, arms, and lips. The disease can be managed by treatments such as laser therapy, phototherapy, micropigmentation, depigmentation therapy, and topical corticosteroids and calcineurin inhibitors.

Get the detailed analysis at: https://www.pharmaproff.com/report/vitiligo-therapeutics-pipeline-analysis

Aclaris Therapeutics Inc. is actively developing ATI-50002 (Janus kinase (JAK) inhibitor), which is currently in the Phase II stage of development for the treatment of vitiligo. JN Bioscience LLC is in the process of developing ChMBC7 as an anti-CD122 antibody for the treatment of vitiligo. Some of the other companies developing vitiligo therapeutics are Dermavant Sciences Inc., 2A Pharma AB, and Incyte Corporation.

Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1019

• The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
• Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Vitiligo Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments | Dermavant Sciences, 2A Pharma, Incyte, Bioscience, Inc., Aclaris Therapeutics, Inc. here

News-ID: 1697343 • Views: 1422

More Releases for Therapeutics

Lipodystrophy Therapeutics- Pipeline Analysis 2018 | Ionis Pharmaceuticals, Inc. …
Lipodystrophy is a rare medical condition which involves problems with fat production, usage, and storage. It is categorized into two types; congenital and acquired lipodystrophy. Download the sample report @ https://www.pharmaproff.com/request-sample/1077 Congenital lipodystrophies include congenital generalized lipodystrophy, familial partial lipodystrophy, and marfanoid progeroid lipodystrophy syndrome; while acquired lipodystrophy includes acquired partial lipodystrophy, acquired generalized lipodystrophy, centrifugal abdominal lipodystrophy, lipoatrophia annularis, localized lipodystrophy and HIV-associated lipodystrophy. Get the detailed analysis @ https://www.pharmaproff.com/report/lipodystrophy-therapeutics-pipeline-analysis The
Dravet Syndrome Therapeutics- Pipeline Analysis 2018 | Zogenix, Inc., Ovid Thera …
Dravet syndrome is a form of severe myoclonic epilepsy that occurs in infants during their first year of age. If left untreated, it can be associated with other types of seizures, and status epilepticus. Children having Dravet syndrome are generally observed with poor cognitive skills and hyperactivity. Download the sample report @ https://www.pharmaproff.com/request-sample/1098 It severely affects the person’s quality of life and around 10-20% of the patient are estimated to die due
Pontine Glioma Therapeutics- Pipeline Analysis 2018 | Y-mAbs Therapeutics, Inc.
Pontine glioma is a malignant tumour which develops from the brain stem cells. Based on the grade of growth, it is categorized into anaplastic astrocytomas and glioblastoma multiforme (GBM). Download the sample report @ https://www.pharmaproff.com/request-sample/1117 Pontine glioma is more prevalent in children than adults. The common signs and symptoms of pontine glioma are squints, swallowing problems, slurred speech, facial weakness, abnormal gait, difficulty in writing and changes in personality and behaviour.
Rheumatology Therapeutics Market
Global Rheumatology Therapeutics Market: Snapshot A rising elderly population and increasing allocations for research and development of new drugs is what is serving to drive growth in the global rheumatology therapeutics market. This has led to the emergence of many new drugs. Their swift approvals by the appropriate authorities has also led to the growth in the market. A report by Transparency Market Research uncovers after in-depth study that the global rheumatology
Bone Degeneration Therapeutics Market
Bone degeneration is characterized by deterioration of articular cartilage covering the joints. Cartilage aids free movement of the joint without any resistance. Reduction in flexibility of the joint due to deterioration of cartilage leads to inflammation, compressed nerves, and pain. Aging is one of the natural causes of bone degeneration, which is also fueled by several conditions such as injuries, congenital disorders, diabetes, and obesity. Symptoms of degenerative bone disorders
Global Dyslipidemia Therapeutics Market
Dyslipidemia is one of the metabolic disorder, which is described by unbalanced level and thickness of lipoproteins and triglycerides. The disorder also includes protein deficiency and over production. These disorders can be caused by increase in the serum total cholesterol, triglyceride concentrations, and low-density lipoprotein (LDL) cholesterol, and a decrease in the high-density lipoprotein (HDL) cholesterol concentration. These condition are mainly associated with cardiovascular or coronary heart disease. The other